Skip to main content
Strategic Partners A/S logo

Strategic Partners A/S — Investor Relations & Filings

Ticker · STRAP ISIN · DK0062502894 LEI · 54930025OZD2GGSQ7L42 CO Financial and insurance activities
Open in API
Filings indexed 501 across all filing types
Latest filing 2019-01-31 Share Issue/Capital Cha…
Country DK Denmark
Listing CO STRAP

About Strategic Partners A/S

https://www.strategic-partners.dk/

Strategic Partners A/S is an investment company that engages in strategic partnerships with businesses that have significant potential. The company's strategy involves taking an active ownership role to create value through its competencies. In addition to its primary focus, the firm may also invest in other equity interests and properties to generate returns. Formerly known as Orphazyme A/S, the company sold its biotechnology activities in May 2022. A new board and management team was appointed in May 2023, and the company officially adopted its new strategy, purpose, and name in October 2024.

Recent filings

Filing Released Lang Actions
Capital increase of 26,060 shares (equivalent to approximately 0.13% of the existing shares) in Orphazyme A/S as a result of an issue of bonus shares to KLSDC and UCLB
Share Issue/Capital Change Classification · 100% confidence The document is a formal company announcement regarding a specific capital increase (issuance of 26,060 bonus shares) to satisfy a license agreement. It details the number of shares, the reason for the issuance, the impact on total share capital, and the expected listing date. This falls directly under the definition of 'Share Issue/Capital Change' (SHA), as it describes a change in the company's capital structure through the issuance of new shares.
2019-01-31 English
Major Shareholding Notification 2019
Major Shareholding Notification Classification · 99% confidence The document is explicitly titled "Major shareholder announcement" and details that Novo Holdings A/S has crossed a threshold, now holding 14.97% of the share capital and voting rights, referencing the Danish Capital Markets Act Section 38. This directly corresponds to the definition of a Major Shareholding Notification, which tracks changes in significant ownership levels crossing thresholds. The appropriate code is MRQ.
2019-01-30 English
Major shareholder announcement
Major Shareholding Notification Classification · 100% confidence The document is a formal notification regarding a change in major shareholding (Novo Holdings A/S crossing a threshold in Orphazyme A/S). This aligns perfectly with the definition of a 'Major Shareholding Notification' (MRQ), which covers notifications of changes in significant share ownership levels.
2019-01-30 English
Regulatory Filings 2019
Regulatory Filings Classification · 99% confidence The document is titled "Orphazyme reports positive results from full data set of Phase II/III arimoclomol trial in Niemann-Pick disease Type C (NPC)" and is explicitly labeled as a "Company announcement." It details clinical trial results, including primary and secondary endpoints, biomarker data, safety profiles, and future regulatory plans (FDA/EMA meetings, filing timelines). This content strongly aligns with an Earnings Release (ER) or a comprehensive announcement of material non-public information, which often precedes or substitutes for a formal Earnings Release in biotech/pharma sectors when major trial data is released. Since it contains the key financial/operational highlights (trial results) and announces a conference call, ER is the most appropriate fit among the provided options, as it is not a full financial report (10-K or IR) or just a presentation (IP). It is an announcement of results.
2019-01-30 English
Orphazyme reports positive results from full data set of Phase II/III arimoclomol trial in Niemann-Pick disease Type C (NPC)
Earnings Release Classification · 95% confidence The document is a company announcement from Orphazyme detailing the full results of a Phase II/III clinical trial. It provides specific data points, p-values, and clinical outcomes, and includes an invitation to an investor conference call to discuss these results. While it mentions a conference call, the document itself is the primary release of the clinical trial data, not just a transcript or a simple notice of publication. Therefore, it is classified as an Earnings Release (ER) equivalent for a biopharmaceutical company, as it represents the initial announcement of key performance/trial results. Q1 2019
2019-01-30 English
Legal Proceedings Report 2018
Legal Proceedings Report Classification · 99% confidence The document is explicitly titled 'Orphazyme reports encouraging arimoclomol clinical trial top-line data in Niemann-Pick disease Type C (NPC)' and is labeled as a 'Company announcement' dated September 28, 2018. It details the top-line results of a clinical trial, including statistical data, safety profiles, and future plans regarding regulatory engagement (FDA/EMA). Crucially, it announces an investor call to discuss these results. This structure—announcing key results and scheduling a call—is characteristic of an Earnings Release (ER) or a general announcement of material news. Since the content is focused on clinical trial results rather than quarterly financial performance highlights, and it is a formal announcement of material, non-financial operational news, it fits best as a general Regulatory Filing (RNS) or potentially an Earnings Release if the company treats clinical updates as equivalent to earnings announcements. However, given the specific nature of clinical trial updates, and the fact that it is a formal company announcement of material news that doesn't fit the other specific categories (like 10-K, IR, or CT), RNS (Regulatory Filings/General Announcement) is the most appropriate fallback. It is not a Call Transcript (CT) as it is the announcement *about* the call, not the transcript itself. It is not an Earnings Release (ER) as it focuses on clinical data, not financial performance highlights. Therefore, RNS is the best fit for a material, non-standard announcement.
2018-09-28 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.